What is the current valuation of the RNA based-therapeutics market in Italy?

The overall market valuation was $439.59 Million in 2024. Read More

What is the projected market valuation for RNA based-therapeutics in Italy by 2035?

The projected valuation for 2035 is $873.25 Million. Read More

What is the expected CAGR for the RNA based-therapeutics market in Italy during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 6.44%. Read More

Which technology segment had the highest valuation in the RNA based-therapeutics market in 2024?

In 2024, the mRNA Therapeutics segment had the highest valuation at $150.0 Million. Read More

What is the valuation range for the Antisense Oligonucleotides segment in 2024?

The valuation range for the Antisense Oligonucleotides segment in 2024 was $120.0 Million to $250.0 Million. Read More

Which application segment is projected to grow the most by 2035 in the RNA based-therapeutics market?

The Oncology application segment is projected to grow significantly, with a valuation range of $100.0 Million to $200.0 Million in 2024. Read More

What are the key players in the RNA based-therapeutics market in Italy?

Key players include Moderna, BioNTech, Alnylam Pharmaceuticals, and Ionis Pharmaceuticals. Read More

What delivery method segment had the highest valuation in 2024?

The Viral Vectors delivery method segment had the highest valuation at $150.0 Million in 2024. Read More

What is the valuation range for the Genetic Disorders application segment in 2024?

The valuation range for the Genetic Disorders application segment in 2024 was $90.0 Million to $180.0 Million. Read More

Which end-use segment had the highest valuation in the RNA based-therapeutics market in 2024?

The Pharmaceutical Companies end-use segment had the highest valuation at $263.63 Million in 2024. Read More

Italy RNA-based Therapeutics Market

ID: MRFR/HC/50894-HCR

200 Pages

Nidhi Mandole

Last Updated: April 24, 2026

Italy RNA-Based Therapeutics Market Research Report: Size, Share, Trend Analysis By Technology (RNA Interference, Antisense Oligonucleotides, mRNA Therapeutics, CRISPR Technology), By Applications (Oncology, Infectious Diseases, Genetic Disorders, Cardiovascular Diseases), By End Use (Pharmaceutical Companies, Research Institutions, Contract Research Organizations) and By Delivery Method (Liposomes, Nanoparticles, Viral Vectors, Electroporation) - Growth Outlook & Industry Forecast 2025 To 2035

Italy RNA-based Therapeutics Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Technology (USD Million)
  1. 4.1.1 RNA Interference
  2. 4.1.2 Antisense Oligonucleotides
  3. 4.1.3 mRNA Therapeutics
  4. 4.1.4 CRISPR Technology
2. 4.2 Construction, BY Application (USD Million)
  1. 4.2.1 Oncology
  2. 4.2.2 Infectious Diseases
  3. 4.2.3 Genetic Disorders
  4. 4.2.4 Cardiovascular Diseases
3. 4.3 Construction, BY End Use (USD Million)
  1. 4.3.1 Pharmaceutical Companies
  2. 4.3.2 Research Institutions
  3. 4.3.3 Contract Research Organizations
4. 4.4 Construction, BY Delivery Method (USD Million)
  1. 4.4.1 Liposomes
  2. 4.4.2 Nanoparticles
  3. 4.4.3 Viral Vectors
  4. 4.4.4 Electroporation
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Moderna (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 BioNTech (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Alnylam Pharmaceuticals (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Ionis Pharmaceuticals (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Sangamo Therapeutics (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 CureVac (DE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Arcturus Therapeutics (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Translate Bio (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 ITALY MARKET ANALYSIS BY TECHNOLOGY
3. 6.3 ITALY MARKET ANALYSIS BY APPLICATION
4. 6.4 ITALY MARKET ANALYSIS BY END USE
5. 6.5 ITALY MARKET ANALYSIS BY DELIVERY METHOD
6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CONSTRUCTION
9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
12. 6.12 CONSTRUCTION, BY TECHNOLOGY, 2024 (% SHARE)
13. 6.13 CONSTRUCTION, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
14. 6.14 CONSTRUCTION, BY APPLICATION, 2024 (% SHARE)
15. 6.15 CONSTRUCTION, BY APPLICATION, 2024 TO 2035 (USD Million)
16. 6.16 CONSTRUCTION, BY END USE, 2024 (% SHARE)
17. 6.17 CONSTRUCTION, BY END USE, 2024 TO 2035 (USD Million)
18. 6.18 CONSTRUCTION, BY DELIVERY METHOD, 2024 (% SHARE)
19. 6.19 CONSTRUCTION, BY DELIVERY METHOD, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TECHNOLOGY, 2025-2035 (USD Million)
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Million)
  3. 7.2.3 BY END USE, 2025-2035 (USD Million)
  4. 7.2.4 BY DELIVERY METHOD, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Italy Construction Market Segmentation

Construction By Technology (USD Million, 2025-2035)

RNA Interference
Antisense Oligonucleotides
mRNA Therapeutics
CRISPR Technology

Construction By Application (USD Million, 2025-2035)

Oncology
Infectious Diseases
Genetic Disorders
Cardiovascular Diseases

Construction By End Use (USD Million, 2025-2035)

Pharmaceutical Companies
Research Institutions
Contract Research Organizations

Construction By Delivery Method (USD Million, 2025-2035)

Liposomes
Nanoparticles
Viral Vectors
Electroporation

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”